Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3084 - Concordance of KRAS, NRAS and BRAF status between primary colorectal tumors and paired metastasis (mts)


08 Oct 2016


Poster Display


Julia Alcaide-Garcia


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


J. Alcaide-Garcia1, T. Pereda1, E. Perez-Ruiz2, F. Rivas2, I. Zarcos Pedrinaci3, R. Villatoro2, D. Perez2, A. Rueda4

Author affiliations

  • 1 Oncology, Hospital Costa del Sol, 29603 - Marbella/ES
  • 2 Medical Oncology, Hospital Costa del Sol, Marbella/ES
  • 3 Oncology, Hospital Costa del Sol, 29603 - Malaga/ES
  • 4 Medical Oncology, Hospital Costa del Sol, Malaga/ES


Abstract 3084


It is well established that patients with RAS-mutant colorectal cancer (CRC) are resistant to anti-EGFR therapies and it is suggested that BRAF mutations may also have a predictive value. However, it is not known which is the most suitable specimen for mutation testing. Although it has been postulated a high concordance of KRAS status between primary tumors (pt) and liver mts, there are contradictory results. In this study we investigated the concordance of KRAS, NRAS and BRAF between pt and matched hepatic and extrahepatic mts.


We examined 31 pairs of pt and mts (liver, lung, peritoneum, lymph nodes,ovary and pleura samples) of patients with CRC treated at Costa del Sol Hospital. DNA was extracted from formalin-fixed, paraffin-embedded specimens, using the DNA Tissue Kit (Qiagen). After verifying the quality of DNA, CLART CMA KRAS-BRAF Kit and Therascreen Kit or Therascreen KRAS RGQ PCR Kit, exon 15 BRAF sequencing and Therascreen Pyro Kit were employed to detect mutations in KRAS, NRAS and BRAF. To evaluate concordance differences, we used Fisher Test for independent cualitative variables, and U Mann-Whitney Test for cuantitative variables.


Concordance rate of KRAS, NRAS and BRAF mutational status between pt and mts of any location was 79.1% (95% Confidence Interval: CI 65.7-92.4).

Pt-Liver mts Pt- Extrahepatic mts Pt-Any location mts
KRAS 78.9% (15/19) 72.7% (8/11) 76.7% (95% CI 59.9-93.5)
NRAS 66.7% (4/6) 71.4% (5/7) 71.4% (95% CI 29.0-96.3)
BRAF 100% (5/5) 100% (1/1) 100% (95% CI 54.1-100)

We found that discordant pairs of pt-liver mts for KRAS showed more frequently a percentage of tumor cells in pt samples


Concordance rate of approximately 80% can be found between pt and corresponding mts in unselected population of CRC patients. Percentage of tumor cells in samples can affect results. More studies are needed to clarify causes for discordance in mutational status of different samples from the same patient.

Clinical trial identification

Legal entity responsible for the study

Hospital Costa del Sol


Hospital Costa del Sol


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings